Shaperon (XKRX:378800) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XKRX:378800 Shaperon Inc XKRX:378800
31 GF Score
Price ₩475.00
GF Value ₩4,340.30
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Shaperon FFO?

FFO (Funds from operations) only applies to REITs.

XKRX:378800
31GF Score
Shaperon Inc XKRX:378800
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Shaperon (XKRX:378800) Overvalued in 2026?

Based on GuruFocus' analysis, Shaperon stock appears to be undervalued. The current stock price of ₩475.00 is trading 89.1% below its estimated GF Value™ of ₩4,340.30. GuruFocus considers Shaperon to be Possible Value Trap.

Key valuation signals for XKRX:378800:

  • FFO:
  • GF Value™: ₩4,340.30 vs. price of ₩475.00 (89.1% below fair value)
  • GF Score™: 31/100 with 6 warning signs

No single metric tells the full story. See the XKRX:378800 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shaperon Business Description

Address Gangnam Ace Tower G9, Suie 218 & 606, 174-10 Jagok-ro, Gangnam-gu, Seoul, KOR, 06373
Shaperon Inc is a developer of innovative inflammasome inhibitors and nanobody therapeutics intended to develop novel treatments for various chronic inflammatory diseases, including atopic dermatitis, systemic inflammatory response syndrome, neuroinflammatory diseases, and chronic inflammation. It offers a range of drug candidates, including a gel-type atopic dermatitis drug for use in the treatment of systemic inflammatory response syndrome, neuroinflammatory diseases and for treating chronic inflammation. The company also provides immunotherapeutic products and a single-domain neutralizing antibody, enabling clients to improve patient's quality of life by developing safe and efficacious drugs and immunotherapies.
31GF Score

Get the complete analysis for XKRX:378800

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₩475.00
Price
₩4,340.30
GF Value